Haemonetics CorporationHAENYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +3.66% | -3.70% | -4.40% | -5.27% | -2.75% |
| Gross Profit Growth | +8.10% | +2.17% | +7.01% | +1.85% | -4.26% |
| EBITDA Growth | +15.28% | +45.44% | +16.95% | -2.50% | +0.36% |
| Operating Income Growth | +28.39% | +138.24% | +35.51% | +13.14% | +17.84% |
| Net Income Growth | +20.02% | +184.68% | -11.32% | +14.34% | +19.33% |
| EPS Growth | +20.97% | +192.50% | -5.33% | +22.73% | +28.00% |
| EPS Diluted Growth | +21.31% | +192.50% | -5.41% | +22.73% | +28.38% |
| Weighted Average Shares Growth | -0.95% | -3.14% | -5.56% | -6.50% | -6.95% |
| Weighted Average Shares Diluted Growth | -1.57% | -3.76% | -6.23% | -6.98% | -7.21% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +81.89% | +0.00% | +128.01% | +113.78% |
| Free Cash Flow Growth | +0.00% | +85.52% | +0.00% | +169.88% | +147.63% |
| Receivables Growth | +0.16% | -1.89% | -0.36% | -3.03% | -7.66% |
| Inventory Growth | +18.28% | +15.11% | -3.55% | -12.01% | -10.69% |
| Asset Growth | +15.04% | +11.63% | -3.10% | -3.29% | -1.60% |
| Book Value per Share Growth | -2.94% | -11.72% | +3.19% | +3.34% | +8.01% |
| Debt Growth | +40.69% | +51.62% | +0.10% | -0.02% | -0.01% |
| R&D Expense Growth | +19.33% | -34.93% | +12.54% | +5.18% | -10.37% |
| SG&A Expenses Growth | +0.00% | +0.01% | +0.00% | +0.00% | +0.00% |